<SEC-DOCUMENT>0001096906-13-001677.txt : 20140115
<SEC-HEADER>0001096906-13-001677.hdr.sgml : 20140115
<ACCEPTANCE-DATETIME>20131112112259
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001096906-13-001677
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20131112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
    <title>utahmed.htm</title>
    <!--Licensed to: sb6208-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center"><img src="logo.jpg" alt=""></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">November 12, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Martin James, Senior Assistant Chief Accountant</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Division of Corporation Finance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. Securities and Exchange Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549-0306</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">VIA FACSIMILE [703-813-6985] and U.S. Certified Mail</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Re:</font></div>
</td>
<td align="left" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Utah Medical Products, Inc.&#160;&#160;(UTMD)</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 10-K for the fiscal year ended December 31, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Filed March 7, 2013</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">File No. 1--12575</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dear Mr. James:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Thank you for your review of Utah Medical Products, Inc.&#8217;s (UTMD&#8217;s) October 1, 2013 response to the SEC comment letter dated September 19, 2013. This is UTMD&#8217;s response to your letter dated October 11, 2013, and which will also be filed on EDGAR as private correspondence with the SEC.&#160;&#160;For ease of reference, I have incorporated the SEC comments in italics followed by UTMD&#8217;s responses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Form 10-K for the Fiscal Year Ended December 31, 2012</font></font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 8. Financial Statements and Supplementary Data</font></font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Report of Independent Registered Public Accounting Firm, page 30</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To confirm our understanding from the conference call held on October 10, 2013, with your representatives, please provide the following:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 140px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td width="1747">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Explain to us how you assessed whether or not your goodwill was impaired in fiscal 2012. Refer to FASB ASC 350-20-35 and Example 4 of FASB ASC 350-20-55-25. To the extent that you only used a qualitative assessment as described in FASB ASC 350-20-35-3A through 35-3G, please discuss how you applied the guidance. If you performed the first step of the impairment testing (i.e., determining the fair value of your reporting unit), please tell us the methodology you used to determine the fair value. Refer to FASB ASC 350-20-35-22 through 35-24.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">UTMD response to bullet 1 of Comment 1.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, UTMD chose to perform Step 1 of the goodwill impairment test for the four goodwill assets on its balance sheet. UTMD compared the carrying amount of the applicable reporting unit to the fair value of that unit. As explained below, UTMD has one reporting unit - the entire company. UTMD&#8217;s 12/31/12 fair value (market capitalization) was $133.5 million based on its $36.05 share price and 3,703,000 shares outstanding. This fair value is far in excess of the reporting unit&#8217;s carrying amount.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For internal purposes,, UTMD also did an analysis of the goodwill on its U.S. books by comparing the carrying amount of each goodwill asset to a theoretical market value of the estimated contribution to UTMD of the products related to the goodwill. In each case, the theoretical market value exceeded the carrying value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Discuss how you determined your reporting units for goodwill under FASB ASC 350. For example, clarify for us whether you consider each of your four subsidiaries based in (i) the United States, (ii) Ireland, (iii) the United Kingdom, and (iv) Australia to be your reporting units for purposes of your goodwill impairment testing. Refer to FASB ASC 350-20-35-33 through 35-46.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">UTMD response to bullet 2 of Comment 1.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following the guidance in FASB ASC 350-20-35-33 through 35-46, UTMD determined that it has one reporting unit. UTMD&#8217;s four goodwill assets relate to products in categories that each span across UTMD&#8217;s formal organizational structure of Utah Medical Products, Inc. and its subsidiaries operating in the U.S., Ireland, the U.K. and Australia. For example, in the case of goodwill related to UTMD&#8217;s 1997 purchase of Columbia Medical, related products are manufactured in both the U.S. and Ireland and are marketed and sold outside the U.S. by both its Utah operations and its Irish subsidiary, UTMD Ltd., despite the fact that the goodwill is on the books of UTMD in Utah. Femcare&#8217;s Filshie product line, which represents the bulk of the value UTMD was seeking in its 2011 purchase of Femcare, is becoming increasingly important to UTMD Ltd&#8217;s financial performance. UTMD&#8217;s business is dynamic, with manufacturing and marketing directed to Utah or the subsidiary that will be most effective in enhancing the Company&#8217;s overall profitability. While discrete UTMD Ltd and Femcare financial information is available and operating results regularly reviewed by UTMD Inc. management, the same is not true of product categories that the separate goodwill assets most closely relate to. In other words, the benefit to UTMD from the Femcare goodwill could not at December 31, 2012, and increasingly will not as time goes on, be attributable to a reporting category for which discrete financial information is available and for which management regularly reviews operating results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, UTMD considers UTMD Ltd. and Femcare to be components of UTMD, Inc. but not separate reporting units as each component (Utah operations and geographic subsidiaries) is economically similar.&#160;&#160;UTMD judges them to be economically similar due to the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each component has the same chief decision maker, CEO Kevin Cornwell.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each component manufactures and sells related medical/surgical devices.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each components sells to similar customers (e.g. direct to hospitals, clinics, doctor&#8217;s offices, and distributors.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All components operate under one real-time integrated management information system (controlled in Utah), with orders being accepted, fulfilled and shipped by the most appropriate (many times different) component.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each component employs similar production processes.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assets and resources (sales, marketing, G&amp;A and R&amp;D) are shared by each component. Each of these resources is fully integrated across all components into one group, managed and controlled in Utah. For example, all marketing employees in every location report to product managers in Utah, and all accountants report to the Controller in Utah.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each component distributes products using similar methods.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each component operates in a similar regulatory environment.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">With respect to other intangibles, please discuss how you assessed whether or not these assets were impaired in 2012. For intangible assets subject to amortization refer to FASB ASC 350-30-35-14 and FASB ASC 360-10-35-17 through 35-35. For intangible assets with infinite lives, please refer to FASB ASC 350-30-35-18. Tell us the methodology used to determine the fair value of the infinite-lived other intangible assets for purposes of testing under FASB ASC 350-30-35-18.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">UTMD response to bullet 3 of Comment 1.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, UTMD determined that there had been no events or changes in circumstances to indicate that the carrying amount (book value) of any of its other intangible assets may not be recoverable. Therefore, in accordance with FASB ASC 360-10-35-21, no assessment of potential impairment was performed.&#160;&#160;In particular, for Femcare&#8217;s identifiable intangible assets, the relatively short period of time between the March, 2011 acquisition and the December, 2012 reporting period end, along with better than projected financial performance by Femcare, indicated no event or change that suggested the carrying amount may not be recoverable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">UTMD does not have any intangible assets with infinite (or indefinite) lives.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Please have your auditors describe to us the procedures they performed in auditing the company&#8217;s impairment analysis of both goodwill and other intangibles. Separately describe to us the procedures performed by The Norton Practice for Femcare and its subsidiaries and by Jones Simkins LLC for the U.S. and Ireland subsidiaries.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Jones Simkins and The Norton Practice response to Comment 2.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Jones Simkins LLC (JS):</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Goodwill:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">JS obtained the impairment analysis performed by Paul Richins, PFO. JS reviewed and gained an understanding of how this analysis was performed.&#160;&#160;JS then recalculated the reporting unit fair value independently, no exceptions were noted.&#160;&#160;The fair value of the reporting unit greatly exceeded the carrying amount.&#160;&#160;JS also agreed the amounts recorded as goodwill to the December 31, 2011 audit working papers noting no changes in the carrying amounts.&#160;&#160;These amounts were also agreed to the December 31, 2012 working trial balance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Intangibles:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">UTMD&#8217;s other intangibles </font><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">on its U.S. books </font><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">had a carrying amount of approximately $157,000 at December 31, 2012.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">JS obtained a detailed roll forward schedule from UTMD that included all of the other intangibles and related accumulated amortization and current year amortization expense.&#160;&#160;The beginning balances (cost and accumulated amortization) on this schedule were agreed to our December 31, 2011 audit working papers.&#160;&#160;JS noted that there was an additional intangible asset recorded during 2012 of approximately $1,400, no audit procedures were performed related to this addition based on our audit judgment.&#160;&#160;JS then reviewed the current year amortization expense for reasonableness based on the stated amortization terms of the intangibles.&#160;&#160;The ending balances (cost and accumulated amortization) on this schedule along with the total amortization expense were agreed to the December 31, 2012 working trial balance.&#160;&#160;Due to the relative insignificant amount of other intangibles, impairment of such intangibles appeared unlikely based on our audit judgment and therefore, further consideration was not given regarding impairment.</font></font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">&#160;</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The Norton Practice (Nortons):</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For goodwill testing, Nortons calculated UTMD&#8217;s 31-Dec-2012 fair value (market capitalization) and noted that it far exceeded its working trial balance carrying amount, so no additional reporting unit analysis was indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For other intangibles, Nortons first agreed year-beginning balances of the assets and related accumulated amortization to its working papers, then reviewed current year amortization expense for reasonableness and consistency with stated amortization terms of the assets, and finally agreed its work papers to the year-end working trial balance of the assets and accumulated amortization. Nortons then considered the events and circumstances of Femcare Group and its industry that occurred during 2012 and satisfied itself that Femcare&#8217;s conclusion of no indication of a carrying amount being impaired was valid. In particular, Nortons identified 2012 improvements in Femcare financial results including sales, earnings and cash flow, and noted that there were no known potentially negative market, legal, business climate or regulatory developments during the year. Given these facts, Femcare&#8217;s other intangibles were not further tested for recoverability or impairment.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Please have your auditors explain to us in detail what is meant by the sentence in your response to prior comment 1 which says &#8220;while performing its 2012 audit work related to the consolidation, Jones Simkins&#8217; <font style="DISPLAY: inline; TEXT-DECORATION: underline">analysis of the intangibles</font> included review of The Norton Practice audit opinion.&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Jones Simkins response to Comment 3.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of our audit procedures for the 2012 consolidated financial statements of UTMD we did the following <font style="DISPLAY: inline; TEXT-DECORATION: underline">related to the intangible assets recorded on the books of the Femcare subsidiary:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obtained the audit report of The Norton Practice on the Femcare subsidiary and ensured that it was an unqualified opinion under U.S. GAAP and the audit was performed under the standards of the PCAOB (U.S.).</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Using our previous knowledge about such assets, we compared the carrying amount to the amount that was expected (based on terms established on the date the assets were recorded) as of December 31, 2012.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result of our 2012 audit we did not identify any events or changes in circumstances which would indicate the lack of recoverability of these assets.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The meaning of the sentence restated in your comment #3 is shown in bullet #1 above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Acknowledgments</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We note that you did not provide all of the acknowledgements previously requested. Please provide, in writing, a statement from the company acknowledging that:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the company is responsible for the adequacy and accuracy of the disclosure in the filing;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="93%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="7%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">UTMD Response to Comment 4.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Respectfully, UTMD has answered this previously.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Thank you for your review of the referenced disclosures.&#160;&#160;I hope that the above responses are complete and to the satisfaction of the SEC.&#160;&#160;If not, please give us the opportunity to augment the responses as needed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/ Paul O. Richins</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Paul O. Richins</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Principal Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Direct tele no. (801) 569-4200</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fax no. (801) 566-7305</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<hr style="COLOR: black" noshade size="2">
 &#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`(D`
MN`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"BBB@`HHHH`***^7O%/[7WPH\'^(];\+:MX2_:BN]3T
M#4KK2KZZ\+?L/_MI^.?#D]S:2&*671/&/@GX`>(/"/B73G92;76/#FMZKI%[
M'B:ROKB)E<@'U#17Q_\`\-Q?!?\`Z$K]L#_Q7K^WW_\`0T4?\-Q?!?\`Z$K]
ML#_Q7K^WW_\`0T4`?8%%?'__``W%\%_^A*_;`_\`%>O[??\`]#11_P`-Q?!?
M_H2OVP/_`!7K^WW_`/0T4`?8%%?'_P#PW%\%_P#H2OVP/_%>O[??_P!#11_P
MW%\%_P#H2OVP/_%>O[??_P!#10!]@45\?_\`#<7P7_Z$K]L#_P`5Z_M]_P#T
M-%'_``W%\%_^A*_;`_\`%>O[??\`]#10!]@45\?_`/#<7P7_`.A*_;`_\5Z_
MM]__`$-%'_#<7P7_`.A*_;`_\5Z_M]__`$-%`'V!17+>"?&.D^/_``MH_C#0
MK/Q58:3KD$MQ96GC;P+XV^&GBF&.&ZGM'76/`WQ&\/>%?&OAZ<RV\CQ6VO\`
MA_3+F>U:"]@BDLKJVN)NIH`****`"BBB@`HHHH`****`"BBB@`K\Q?\`@F/X
MJUSQ-I?[;T.O^)]8\1W7AS_@H_\`MH^'K&'6]<OM9N?#V@Z?\8M<70-!LXK^
MZN9M'T6QTHVRZ)I4*VUA;Z:;?^SX%M#%G].J_FZ^)'Q=_92/Q-_;1_:/N?V5
M/CYX&^'W@3]ISP]^S!^V9\6/@U^TOKWPRA^+NLV^O^$O@KI7CGQM\#O`OQ`\
M,1_$+P]I%SXCT31;W4K=8/B/=>%I]4%O::ZIETFY`/+?$?P1^'GQ%\`_\$8?
MB#XN'CO7?$O[2W[4UEX!^+WB'_A</QCTUOBA\+D_9Q_:J\6>'=$UF'1_'FFZ
M?>Z#<7OA3P1XELY[>TC>^FT/1[YKB>)YA<^XW7[1WC3X1?\`!0'X$?%G1$^,
MVE_L-7_C>[_X)=V^FZGI^H7_`,"-/CADTK2OA#\>K'QEJ?B"_O=3\::G^U=X
M<\1_LT7FM:O'<'4?"6K^%]274II))YKWTG1?VTOV7_BMHO[!GCWXO?LOZ[\'
MO@-;_&'XUVG[(_Q+A\>>'(-`^$'Q,_9G^&G[1W@G5KGQ?X"\%ZUHNH>%?!Z?
M!7X<?&B7P_J/]G^,O!NA62Z-!K]MX?U6XT>YM-/Q%\4_@[XP_P""<%OK7CK]
MAWQ]%_P3'M_A[X5\6VK/\2-13XYZ5^SSX.N='\?^$OVC+[X:Z;-:?$+3;711
MHFD_&&2>U^*U[\<[32+,>+;_`,,S>,!>>'P`>%_!W]H']LJS_P""?/[:+^'?
MV>->^)>CZ%\5_P#@J)IOASXS:G^U)X:T'Q+_`&/I'[2G[2-A#?:=H^MZ5?>)
M?"\?PWMK8:)X;TB35O.6R\,V,FBMING3Z9!!^OW[)GC-]*_8$_9G^(7BG5KW
M59--_8_^#/C+Q'KNL7ES>ZCJ3V?P7\-ZWJ^K:I?WLLUY=WMXT=Q>7UY=SRW-
MQ/)+-<2R2N[GXB^&7QV\*^(/AU^U_P#!;]E3]A_Q+\9/@%\+?C'\5O`'Q*M?
M#GQQ\%Z;JOQ@\0_'7P;X<_:5^*_B+X<V7C'Q'%=ZO:>/[/\`:(DU32WU#QKX
M634-;U2^L-&DTBP@LIH_5OV0_P!JW]D_]LCPEK/[*GP+\'>*!\!-!_8O^`?B
M'2)]2GOM#MYO@_\`&^T^+?PAL/A:\#ZLWCOPWXV^'<'P9\1^%/&::G=1:II>
MK>7':ZM<ZA:7%VH!\(?LJ?M:_M%6O[+]Y^P=XK^)%SJG_!0?Q-X(\*ZS^SS\
M3/$$,E[J7B;X`_M*^`M;^*OA#]I&XM;ZZ>35H?V9-/@^(WPM\5J[R6%]\0?A
M%X(T?4;J"7XI:#]I^</V!]0U_P#:X_:+^'/B[Q_\+/B%^T?;:1_P3F_X)'^,
M;KQ)J/[1WB+P%:_!GQYKMO\`'^T^*'CN?PDOC'1X_'&N>*/$?@I-4\5&UL-1
MO]4G\$VVGZF93J4,4OZFZ%^TI\`I?VE/#'PC^`'[,#>/_P!K?X2>#OC'\`O#
M[W>K:)X8M_A?^R]\*/'/@#PUXCU_QI\4[]/$.H>'OAUXQ\?Z3X2TOP1X:M-$
M\5>-_%FO^'=2NH=#@TO1?$>LVGQYX^^'WP]_8-^'NB_'2'_@G1\:/A99^%-1
M^"7[/NK?\*H_X*`Z]I$6JZ???M$/X.^`VD2PZ9\3=%3XC>`H_'?QVO=:BG\:
M:7IVKZ#X?\3>)=*UOP\;+3SILH!SOP$^!WP_\=_\$ROVHOVI/%GQ"^*?P]^/
M/@GXC_\`!33QIH_[3&A_&KXIZ'XQ\!WOP;_:=_:./@77F?\`X3!O#M]X=\$Z
M/X1T+2G\'ZSHE_X-U'PKHX\.ZKH5YI<UQ!)\X_"O]HW]I/X]_M(?!GX7_%OQ
MMX_^&.A_MG_%S_@G^O[3%IX;\5:[X/?02/\`@D[KW[37B7X$>$K^QU"QO_AE
M8?''XL^%HM+\60^"[G0/$.K:%I_B+P[;7L-QK%Y/7W_\,/AW\&/&WQ$\=?LV
M:#^P[XUU'2/A-\6O!GC/]J7X'^(OVP-:U[X2?#_QO^TMXXUCXS_\)7IWP9U7
MQA??#?XRZ`\&N/\`&GQEIFH:9HGAM;[6-0\.^$]%\5^+O#^IZ%I_U3^V+\/?
MV/?`'B'P_!\5O@5J/CG6?V[_`-H3X?>%?$&OZ)XFUK1]4\/_`!-^`'[/_P`3
M?B3\*_B;H^M0^)-*U;X<ZYX'\*?!&YT+P[XD^%USX>\26FLZC87TMPZ2:E=4
M`=+\<?!7PX_8G^$'Q+\4_LW^#/$^@_%?XXS>#/@[X"\)>#=9\7>*4U+XC>(;
MO4])T/Q5X7^&VM^([GPL/$/@O0]3\2_$CQ;?:59:1J?B3PSX$NAK^IW<>E6;
MV_Y"_#WX^?%&R^#7[&?[*_C?QO\`&*V^,O['7_!8W]GC]F+QSJOQ&OM4\,_%
MCXJ?L]Z[X9^(_CS]G;QM\4;*SU*9]7B^)/P3UCP?:>*HKZ^U33-?\;>#/%,U
MPLLMH4B^X?V=/CO^Q=\0_P!F#2/^"CW@:U_:"^)7B/X.HLFK^"_C;\6/B+XD
M^,WP<\>:YH4/@W4?`?BCP5XZ\9WGACPYXFTWPE\3+V?2=073A:>(O"'C,>,M
M!U76--\5V&L7F?KOA/X$?MT?%CQQ^TI\*OV,O%7Q?TCPA\5?!7PJO_VB[#]H
MOQ%\`M7\>>,/V1_B1\0O#D/COX(>%_#VM6EKXT7X%^+?&GQ8\-Z)\0_$&K?#
MZY\83Q^(_#?AW4M?\,VVC7LH!^X]%<MX)\'Z5X`\*:)X-T.Z\17VDZ!9_8K*
M[\6^*_$WCGQ)<1>;),9-7\6^,=5USQ/KMV7E?-YK&K7UUL"1>=Y4<:+U-`!1
M110`4444`%%%%`!1110`4444`%?@I^RW^S1^SYX$^/'[;7C/]KG5_@ZNO>)_
MV^/'_P`>OA#X;\9?M$:!K/AVWL+?4H+WP+XTU7X01_$*7P7HOC70K^WBU/2S
MXM\'Q^+O#FM6UOJL7V'5;>&Z3]ZZ\)U[]ES]F7Q3K6I^(_$_[.GP)\1^(=;O
M9]2UG7M>^$7P_P!8UK5]1NG,ES?ZGJFH>'KB^O[VXD)>>ZNYY9Y7):21F.:`
M/Y>?@A^Q!I_PZ^$VA^'/$'Q`^"6L77[4WPK_`&Q/V4_VL/#FJ?M+?"/Q?K_[
M,.@_'GQY\=M2^'W[5/[.6H>(?B+-X>T&.^\(>-M&\/?M"_"WX=ZMI-_X_P!+
MU#P=XAM=*N_%'@/7-+U_]%/$'QG^)?B?_@GO-^Q5;0_`GPW\==<_9[MOV5]:
M^-E_^T7\`M2_9ITBQO\`P6GPE\2?'/1!9_$D_%C6-*A\.M?>./#7PPO_`(9:
M7XDN-7;3_!^M7=AIHNO%@_5S_ACW]DC_`*-:_9S_`/#(_#/_`.9BOY^?^"Q'
M_!53_@DU_P`$J;&]^&NG_LK_`+-G[07[7-]IK3Z1\"?"OPM^%MG8>"!=VGG:
M7KOQG\5P^$=0C\&Z=/YD%U9>&;6UOO&FNVCQ36^EZ9H]VGB&``]H_8S\3:E^
MP+8_MC_"_P"'O@WP1\5M`\6_'K0?%/[.7C:Z_:P_95\/^!/$/@/PQ^RM^S9\
M#?#E[\1M2U+XO-\1O"UT/$7PGUVX\1QZ?\,/$.HQZ:L=WI&G:E-<PVAXG]BC
MX8VG_!,SXGZ/K&A^-?A7^UAX3^*7[*'PS^'7QB\0?"'XZ?`'PIXC\%_M$>`O
MC+^T#\8?%FN:;X.^,/Q7^'MCJ?PB^(6I_M&ZW9^'+K3/%%]XI\*2>$;>+6?#
MLECK/VW3_P"4+_B*QO/^D1?_``3>_P##=R__`"OIR?\`!U?>,RK_`,.B_P#@
MF]\S!?\`DG<HZD#K_9QQ]<'Z&@#^N'X*:3J?[,W[86O?MO0^(?@K\5(_VJ_"
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M`(.#_P#@HWX&_P""/OQ'_9K\&?!K_@GI^PG\4K#XV^"?B!XGUR[^)OP7T>*[
MTB[\(:[X>TJTMM*'A6#183;7,.LRRW)NTN)?-BC$31H&#@'Z,?MD:/\`"KX\
M?M%>%_B3\(],\$?!K]I#X9?$SX#)X`_;_P#`_P"UA\#O"OA[7_@1HGBWPKXM
M^,'@;XN>%]"^*>G?$'XA:!+H$GQ"^'6G?!WQQ\,O&?AK5-0UG2_$NB^*O#=M
M>:I>Z%]'_MW:YX$^-_B/]B[4/AI\7_@7KMI\'?VG_$/Q*^(4MQ\;_A=HYT7P
M;?\`[)W[3GPMM=3@CU7Q3:OJLLGC?XD>#M).GZ:+F^2'4Y=2>`6&GWUQ!_!S
M_P`157B[_I$__P`$Q/\`PSFI_P#RTKZ;_9-_X.G_`-G#5/BWI.B_MK_\$L?V
M//#?P9UEH+"^\;_L^?"'P]=^+_!-U/=0I_;^H>$_&MGJUMXOT*V@:5M0TS2-
M3T36X(E:ZTX:S<)'I%R`?T5?M!?LR65Q^SU\#O''[,7[0/[.?@O]J'_AG;]F
MS]G']L/X1:S\:_AM%\/OVD_AA\/].\$Z=?P:YJUKXJ71;+XW?`6ZL-;U/X-_
M%:&XE-[H#:_\-=:NM1\*>(-&?0/K']BCXO-^Q5\*-1_9/U6Q^'WQ6\)?#CXH
M?%*?X(_&[X?_`+1G[-%GX/\`&?PI^)GQ5\5_$SPY)\3-*\8_%?PIXW\!^./`
M-CXUD\,>-X-,\'>,-,\1S>'CXD\)ZCK-UK;:'8_:WP'^'?\`P3A_:?\`A7X3
M^-W[/WPB_9*^*_PJ\;V(U#PUXT\(_"'X8W^EWT:MY=S:SHWA:*]TK5].G#V>
MKZ'JUK8ZSHU_%-8:K86=Y#+`GK__``Q[^R1_T:U^SG_X9'X9_P#S,4`=G\"O
MB/K7Q<^$/@#XD^(_!L'P\U_Q?H$&JZSX&MO'?@OXG0^%-2:6:"\T,>/OAWJ>
ML^"/%+V$\#P2ZIX:U2]TV257CCF+QNJ^LU@^&/"OACP3H.G>%O!GAO0?"/AC
M1XI(-(\.>&-'T_0-!TN"6>6ZEAT[2-*M[33[&*2YGGN)([:WB1YYI96!DD=C
MO4`%%%%`!1110`4444`%%%%`!1110`445\0?\%'/VW/`O_!.W]C'XY?M;>/(
M[?4(/ACX5D;PCX8FG:!_''Q(UZ>+0OA[X+A>,B=4U_Q5?Z;;:E=6ZO)I>B+J
MFLNA@TZ8J`?AE_P<>_\`!?"+_@F]X'/[*W[+^L:9J/[:_P`4O#1O=0\0+]FU
M*U_9P\!:S"\5GXRU&QE2:UNOB/XDA,LGP^T"_1[?3+2,^-->M9M/'A[3/$O^
M6EXJ\5>)O'/B77O&?C3Q!K7BSQ=XIU>_U_Q+XG\1ZG>:SKVOZYJMS)>:GJ^L
M:MJ$UQ?:CJ5_=S2W-W>7<\MQ<32/)+(S,37??'SXZ?$_]IKXT?$S]H#XS^)[
MSQC\4OBWXOU?QKXT\0WKN6O-7U>X,IM[.%GD6PT?2[86^DZ#I%NPLM&T2QT_
M2;".*RLH(D\BH`*DA_UL7_71/_0A4=20_P"MB_ZZ)_Z$*`/][/X2_P#)*OAG
M_P!D^\&?^HYIM?Y]/_!\'_R7?]@+_LDGQN_]3'P+7^@M\)?^25?#/_LGW@S_
M`-1S3:_SZ?\`@^#_`.2[_L!?]DD^-W_J8^!:`/X7J***`/V:_P""-'_!9GX]
M_P#!)'X\6NO^'[K5_'W[-'CO5;"#X\_`*XU)QI/B+2]\5M+XU\$Q74OV#PY\
M4_#UDOF:/K4:P6VO6L"^&O$K3:5-;W.F?Z^_[/'[0/PF_:I^"?PV_:&^!GBV
MQ\<?"GXK^%[#Q9X/\16)V_:+"]5EGL=1M&/GZ5KNBW\5UHWB'1+U8]0T37+#
M4-)U"&&\LYHE_P`&ZO[4/^#0/_@J9JGP8_:#U7_@F[\5_$4K_"7]HJ\U/Q3\
M")-3NF:V\$?';3=+:\U;PS8/,WEV>D?%?PYI<JK:!A%_PG&@:'%I]L+[Q7JL
MTX!_I44444`%%%%`!1110`4444`%%%%`!1110`5_G@?\'I/[=4'BCQW^S[_P
M3\\&ZS,+7X9W%[\<OC9ID;R)'/XK\0^'M/T_X1V<ZHPCE72O"NN>,M49)`VZ
M7Q#9R;$:UBD?_0_K_&+_`."_GQ4G^,/_``60_P""@?B>:Y>Z70?CUJ_PKMR\
MOFK!!\%-'T7X0"UBYQ&D,O@B4&)<>7(9`PW[B0#\>Z_H-_X-PO\`@E[H_P#P
M4E_;G6]^*_A\ZY^S1^S#H=K\7?C+IMPC_P!E^--5^US6_P`-/A7?RKD&S\9>
M(+&]U37K5AMU#P9X3\4Z:)()[ZWF7^?*O]23_@S\_9^TGX8_\$H?%?QH^Q!?
M$W[2GQN^)'B*]U)HU6:?PK\-;>#X:>&=,#@;GM-/UK1?&NH0!B0L^NWFT#<<
M@'^7KXD54\1:\L:)&BZUJBI'$BQQQH+Z<*D<:`(B(`%1%`55`50``*R8?];%
M_P!=$_\`0A6OXE_Y&/Q!_P!AO5?_`$OGK(A_UL7_`%T3_P!"%`'^]G\)?^25
M?#/_`+)]X,_]1S3:_P`^G_@^#_Y+O^P%_P!DD^-W_J8^!:_T%OA+_P`DJ^&?
M_9/O!G_J.:;7^?3_`,'P?_)=_P!@+_LDGQN_]3'P+0!_"]7]!7_!(G_@F!I'
M_!2_]AS_`(*JZ=X8T%;S]I7]G?P_^SY\8/V=M5MD<ZGJ.JZ=;?'6?QO\+0L8
MW7=E\4_#VDPZ796KE(X?&>F>#M3>006%Q%-_/K7]]'_!C?\`\AK_`(*0?]@O
M]ES_`-*_CQ0!_`RZ/$[QR(T<D;,DD;J4='0E61U8!E96!5E(!!!!`(KVG]FS
MXUZY^S9^T3\!_P!H?PS`MUXA^!/QD^&?QAT6S=MD5]J?PV\9Z+XPL["<D%3;
M7TVCI:7*.&CDMYI(Y$>-F4_=W_!</]G/2?V5?^"L'[;_`,'?#FGII7A:U^,^
MI>/?">F0H$M=-\-?%_2M)^+.CZ78HH54L=)M/&B:5:1J,10621=4-?E-0!_O
MC_#OQUX?^*'P_P#`WQ+\)W7V[PK\0_!WAGQSX9O1M(O/#_BW1;+7]&N@49D/
MVC3M0MI?E9E^?Y6(P:[&OR!_X($?%&?XP?\`!'#_`()]^+[FZDO)]/\`@-IW
MPWDN)I3/*[?!GQ%XA^#VUY3RS0CP((<,2R>7L8DJ2?U^H`****`"BBB@`HHH
MH`****`"BBB@`K_$2_X*X6%YIO\`P54_X*4V]];O;32?MY_M<:@D<@`9K/5O
MCUX]U33IQ@GY+K3[RVNHNYCF0D`Y`_V[:_R#?^#GGX`:S\#?^"R/[4VJS:5/
M9^%/C7?>"OC%X0U$VDEO9ZJ?%?P\\)2>,3;RL/+N9[/QS'X@BO6B8X>2)Y`C
M2[:`/Y^:_P!>G_@V`U'2M<_X(;?LCVFBB-9M.'Q\T/4XU8'R];7X^_%*XN/.
M(R%>>.^M;HCJ([A"0#D5_D+5_I"_\&5_[8>C>,/V9OVB?V(=<U6%/&GP9^(O
M_"[O`^F3R!;G4/AG\3K32]$\2#3H2Q,MMX4\>Z"MSJLBJJP3?$'25;)N`:`/
M\Z[XD:#J?A7XB>/?"^M0-:ZQX;\:>*=!U:U<,KVVI:/KE]I]_`RL`RM#=6\L
M;!@&!4@@&N-5MK*V,[6#8^AS7]$7_!S9_P`$]?$?[#__``4P^*7CK3-!GM_@
M;^UYK.N_'_X5ZY!;&/28_$7B74%OOB]X(\U&:&'5/"_CW4;W5$T]!'Y'A7Q5
MX4G5!]H94_G;H`_W%O\`@G1^U[\$?VV?V/?@9\</@;XTT+Q1H>K?#?P;9>)M
M(T[4[2ZUOX?^,]/\/V5EXE\"^,M-BF>\T+Q%X?U:UO;*>UU"*'[;;PPZMIS7
M>DWUC>W'^?!_P>)_MA_!7]HO]M_X(?!WX/>,-&\>W?[,'PM\3>'/B;X@\-:A
M:ZMH.F?$#QYXFM-6N_!,.J6,T]I>ZOX6TC0=)D\0+:RR1Z9JFL2Z'=/'JVEZ
MG:6O\F?AGQYXX\%+J:>#?&7BOPDFMVOV'64\,^(M7T%=7LL./L>IKI5Y:"_M
M<22#[/="6+#O\GS-GE"2>3R3R2>]`!7^@;_P8Y^%M3CTG_@HQXVDB9=&O-1_
M9I\+6LQ0[)M3TVV^-.K7\2R9P6M;75=->1`"0+N-B0"N[_/R&3P!DG@`=Z_U
MT_\`@W<_8OA_X)A?\$EM%\5?'N.W^'?C?XHP>*?VMOCU<^(5:PE^'_AJ\\,6
M5QX>TCQ&T^)=.;P=\*_#.DZKXBL+B.*31?$&H^)+.:,30RE@#^$K_@ZAU[2M
M<_X+;?M4QZ7-'.=#\/\`P'T'4WBV%5U6T^!GP_N;F$LA.Z2!+R"&7?\`.DJ/
M$P'E@5_/#7UK^WG^TS??ME?MG?M-_M1WT<]O'\;OC+XX\<Z-8W((N-*\)ZAK
M%Q#X+T6;))\S1/"-MHFD-D\FRS7R50!_L"_\&O\`8W>G?\$+OV%K>]@>WFDM
M/VBK](Y,;FM-4_:T^/.IZ?.,$_)=6%Y;7,??RY5R`<@?OG7Y\?\`!)[X'7G[
M-W_!-+]AOX+ZK:?8->\&_LT?"H^*;+RFA-IXQ\1^&++Q9XRMGC;#"2'Q3KNK
MQRE@&>16=@&8BOT'H`****`"BBB@`HHHH`****`"BBB@`K^.C_@\:_8.O_CK
M^Q;\-OVR_`VB2:AXR_9"\57UEX_%C`\EW<_!'XIS:/I.KZK.D69+E/!GC?2_
M"%[DQLNG:)K?B?4II(K:VG8?V+UQWQ#^'_@WXK^`O&GPO^(GA_3_`!9X!^(G
MA77_``3XT\,:M%Y^F^(/"WBC2[K1==T>^B!5FMM0TR\N;678R2*LI:-TD56`
M!_@<5]Q_\$Y?V\/BM_P3;_:\^%/[6/PD(O\`4O`VI26'C'P=<W4EII/Q'^&N
MN^79^-_`&LRHDHBM]=TH&33;][>Z.A>([+0_$=O;37FCVR'W_P#X+)_\$N/B
M1_P2F_;&\7_!+7K?4]8^#OBRXU+QK^SC\2[F"0VGCGX77=^XL["\O1&ELWC?
MP,TT/AGQWIZ>5)'J<%MKD%K'H7B+0I[K\G:`/]E3XE_#;_@GY_P<<?\`!.+2
M)[768O%7PU\?6RZ_X%\;Z-_9T7Q8_9O^,^FZ<UO/%=6;R7!T'QMX4EOY=)\6
M^$]29]'\5^';UU62^T'6M&UMO\T/_@I=_P`$)_V^O^"97BC7+CXC_#'6/BG\
M![>[F/AS]I+X4Z+J?B'X<:EI9><VDOB^&S2]U7X7ZV8(2;S1?&<=G:BY$J:'
MK7B&Q2/4INZ_X-\OVE/^"@WPE_X*&?!;X/\`[!_B9)K[X]>-M%T#XI_#'QA;
MZEK7P<\3>`-'$^J>+_%OQ!T*QN+>YL%\!>$;;7=?L_%V@W.F^*=,6VDTW3+Z
MYBU6XT;4_P#8AEACN(9+>YBBGAGB>&>&6-9(9HI$*2Q212!D>*1697C<,K(2
MK`@F@#_`,KN_AM\+OB7\9/%^D_#_`.$GP_\`&GQ.\=:]<1VNB^#_``#X9UGQ
M=XEU2>61(DCLM%T&SO\`4+CYW0,T=N43<&=E7FO]N#QY_P`$T/\`@G7\4-9?
MQ'\0_P!A3]D7QCX@ED::?6]?_9X^%%_JUU*[;WDO-0F\*F[O)&<EF>ZEE8DD
MD\U[]\)?V>_@)\`].ETCX&?!+X2?!K2YXTBN-/\`A9\.?"'@"SN8XR"B7-OX
M4T?2H[@*54CSEDP0#U&:`/XA?^""O_!K/XK^''COP5^V5_P4T\,Z19ZSX1OM
M,\5_!W]D^YN++7VL_$5H8K_1O&?QTFM)+G1O/T*[6"_T3X8V5SJ<;ZE#;W7C
M>ZA%E<^$KK?_`.#L#_@MQX7T+P+XH_X);_LO>,K76O&_BR2*Q_:_\:^';Q+B
MR\%^%K:6.[7X#V6I6KE)/%GB6[BMI_B9%;RE=`\-V_\`PA6HB?4/$GB"PT+]
ME?\`@YH_:'_;]_9>_P""=&L_%G]AS7K#P?I=IXJL?#7[1?CS1]-OKKXL^`?A
MEXM5="TOQ3\-]42<Z?X:B'BF[L-`\4^)!I]UXCT2#7]*U7PW>:(UEJ.KVO\`
MD;W]_?:I?7FIZG>7>HZEJ-W<7^H:A?W$UY?7]]>3/<7=Y>7=P\D]U=W5Q))/
M<7$\CS3S.\LCL[,Q`*E?H_\`\$BOV3M4_;7_`."D?[('[/UOX:D\4>&/$'QK
M\%>)?BI8;'^R1?!GP#K-IXT^+-Q?SB.2*UAD\"Z)K6GVLEP!#<:M?Z=IX+3W
ML,;_`)P5_J+?\&J'_!'_`%7]BC]GK5?VT/C]X7ET;]I/]J7PWIL7@_PWK5B;
M?7?A-\`)9K;6]&TR^AG`N--\4?%"_ATWQ=XEL)5CN=,T/3?!>DW<5CJ\&OV0
M`/ZX$1(T6.-%2-%5$1%"HB*`JJJJ`JJJ@!5`````&*=110`4444`%%%%`!11
M10`4444`%%%%`!1110!^?/\`P4L_X)L_L\?\%1OV:]>_9V^/NER6LBRRZ]\,
M?B=HMI:R>-OA#X^BM9+?3_%WA:XN0JSPNCFQ\2^&[F:/2_%.AR3Z;>M;W"Z?
MJ6G?Y%W_``4K_P""6/[5_P#P2T^-5[\*?VBO!\TOAC4KZ^/PN^-/ARUO;GX7
M_%K0;=M\6I>&=:EB46.M0VS1-K_@S5S;>)/#MPV+JUGTV;3M5U#_`&UZ\8^/
M_P"SK\#/VJ/A?XA^"W[17PL\&_&'X7>*(@FL>#O&^CP:MIKSI'+';:II\K[+
M[0]>T[SY9-(\1:'=Z=KVCW#?:M*U&SN564`'\D?_``9__P#!+^/X%_LZ^(_^
M"BGQ5\/"'XJ?M.:?/X5^"4.I6JB]\*?L_:5JL<E]XAM5E03VEW\6O%>E1WZ.
M1^^\'>%O"VH6,YL_$=VDO]H=<SX+\&^%_AUX.\*?#_P/H=AX9\%^!O#>A^#_
M``CX;TN(P:9H'ACPUIEKHV@Z+I\)9C%9:7I=E:V5K&68I!`BEF()/34`%%%%
M`'!?%/X9>!OC5\-?'WP@^)WAZQ\6?#OXG>#_`!%X#\;^&=3C\VQUSPOXITJZ
MT;6M-G'WD%U87D\:31E)[>0I/!)'-'&Z_P"*=_P4^_8!^('_``3@_;B^,/[)
M'BB#4M7M/#?B"/5?A+XD>U9I?B+\)_%LTMY\.?%%HEO'Y=SJ%[IK#1=>MK)9
M(K'QCI'B#18B\FGMG_;NKYS\??LB?LQ?%3XX_#3]I7XE?`SX;^._CM\'-#U+
MP[\+OB9XK\-V6N>(O`VEZIJ4.KSKX??4%GL[._M=2BDN]'U@6C:QH$E_K`T*
M_P!.37-96^`/X=?^#=K_`(-G=?DUWP-^W?\`\%'_`(?2:-I6D3:=XM^`'[+7
MC&P,>K:KJ<#Q7VA_$OXW>'[M-VF:582+#?\`A3X9:M$NHZI>I!JOC:QLM*MK
M?0=>_P!!:BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
;`HHHH`****`"BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
